Overview
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Description
A phase IV, prospective, single arm, multi-center, observational study to collect safety and outcome data of Zepzelca in adult participants with extensive stage SCLC previously exposed to at least one line of treatment with platinum-based chemotherapy. Patients enrolled in the study will be encouraged to complete patient reported outcome (PRO) questionnaires.
Eligibility
Inclusion Criteria:
- Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
- Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
- Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
- Patients initiating Zepzelca treatment in second-line.
- Patients who are sensitive to platinum-based chemotherapy with CTFI≥180 days. The CTFI is defined as the length of time from last platinum dose to time of relapse or disease progression.
- Eastern Cooperative Oncology Group performance status (ECOG) ≤1
Exclusion Criteria:
- Patients who discontinued a prior Zepzelca treatment due to adverse events.
- Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
- Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.
- Known CNS involvement prior to Zepzelca treatment.
- Patients who were treated with Zepzelca in later lines rather than in second-line treatment